Broad Institute Licenses CRISPR/Cas9 to AMRI

Aug 23, 2016 | a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – Albany Molecular Research (AMRI) announced it has obtained a non-exclusive license for CRISPR/Cas9 technology from the Broad Institute.

The contract research organization said in a statement that CRISPR offered "significant utility" for pharmaceutical research and development, especially drug target assessment, *in vitro* model development, and optimization. AMRI reported that it has already used CRISPR/Cas9 in both customer and internal R&D projects.

"The application of CRISPR-Cas9 technology benefits a number of the specific services that AMRI provides to its customers, including protein production, cell line and assay development, high content screening and analysis, and target validation and assessment," the firm said.

Financial and other terms of the agreement were not disclosed.

AMRI is the latest CRISPR/Cas9 licensing deal for the Broad Institute and the first since July, when Broad signed a CRISPR licensing deal with Evotech. Broad's foundational CRISPR/Cas9 patent is being challenged by the University of California in a patent interference proceeding; however, Broad has more than a dozen patents involving CRISPR.

Filed Under Gene Silencing/Gene Editing | Business News | Drug Discovery & Development | licensing agreement | Broad Institute | CRISPR

Related Articles

Aug 29, 2016

Top Five Articles on GenomeWeb Last Week: Illumina, Breast Cancer, the Broad Institute, and More

Feb 23, 2016

Caribou Bio Grants IDT Non-Exclusive Rights to Commercialize RUO

CRISPR/Cas9 Reagents

Sep 22, 2016
Monsanto Licenses CRISPR From Broad Institute for Ag-Bio Applications

May 17, 2016
Bayer Inks CRISPR Patent Licensing Agreement

Jul 06, 2016
Evotec Licenses CRISPR Tech From Broad Institute, Harvard

Nov 24, 2015
Regeneron Licenses CRISPR-Cas9 IP From ERS Genomics

We recommend

Horizon Expands CRISPR-Cas9 Portfolio with Broad Institute Licensing Deal
GenomeWeb, 2014

Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich
GenomeWeb, 2014

Sage Licenses CRISPR-Cas9 Technology from Broad Institute
GenomeWeb, 2014

Evotec Licenses CRISPR Tech From Broad Institute, Harvard
GenomeWeb, 2016

Horizon Discovery Licenses CRISPR-Cas9 Technology
GenomeWeb, 2014

Clontech Licenses CRISPR-Cas9 Technology from Broad Institute
GenomeWeb, 2014

Powered by TrendMD

Privacy Policy. Copyright © 2016 Genomeweb LLC. All Rights Reserved.